Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05HOH
|
|||
Former ID |
DNC013490
|
|||
Drug Name |
Tyr-Sar-Phe-D-2-Nal-NH2
|
|||
Synonyms |
CHEMBL254926; Tyr-Sar-Phe-D-2-Nal-NH2
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C34H37N5O5
|
|||
Canonical SMILES |
CN(CC(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CC3=CC=CC=C3C=C2)C(=O)N)C(=O)C(CC4=CC=C(C=C4)O)N
|
|||
InChI |
1S/C34H37N5O5/c1-39(34(44)28(35)18-23-12-15-27(40)16-13-23)21-31(41)37-30(19-22-7-3-2-4-8-22)33(43)38-29(32(36)42)20-24-11-14-25-9-5-6-10-26(25)17-24/h2-17,28-30,40H,18-21,35H2,1H3,(H2,36,42)(H,37,41)(H,38,43)/t28-,29+,30-/m0/s1
|
|||
InChIKey |
GNWOYARHUGPZGJ-JBOQNHBVSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Estrogen signaling pathway | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Enkephalin release | ||||
Pathway Interaction Database | IL4-mediated signaling events | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | TCR Signaling Pathway | |||
GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | ||||
Opioid Signalling | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.